MedPath

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Phase 3
Completed
Conditions
Leukemia, Myeloid, Acute
Interventions
Registration Number
NCT01721876
Lead Sponsor
Boehringer Ingelheim
Brief Summary

To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients \>= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
666
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo and CytarabinePlacebo-
Volasertib and CytarabineVolasertib-
Volasertib and CytarabineCytarabine-
Placebo and CytarabineCytarabine-
Primary Outcome Measures
NameTimeMethod
Objective Response (OR)Response assessment was performed at the end of every 2nd cycle, (i.e. at the end of Cycle 2, 4, 6, 8, etc., and at end of treatment), i.e. up to 52 months.

OR is the number of patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi), where OR was based on the best response attained during the treatment period.

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)From randomization until death due to any cause, up to 1557 days.

OS is the key secondary endpoint and was measured from the date of randomization until death from any cause. Patients who were lost to follow-up were censored on the last date they were known to be alive.

Event-free Survival (EFS)From randomization until disease progression or relapse or death from any cause, up to 1557 days.

EFS was measured from the date of randomisation to the date of progression or relapse, or death from any cause, whichever occurred first.

Relapse-free Survival (RFS)From randomization until disease progression or relapse or death from any cause, up to 1557 days.

RFS was defined only for patients who achieved best overall response of CR or CRi; it was measured from the date of achievement of a remission until the date of relapse or death from any cause. Patients not known to have relapsed or died at last follow-up were censored on the date they were last examined.

Trial Locations

Locations (122)

Princess Margaret Cancer Centre

🇨🇦

Toronto, Ontario, Canada

HOP Côte de Nacre

🇫🇷

Caen, France

HOP Haut-Lévêque

🇫🇷

Pessac, France

Hospital Doutor Amaral Carvalho

🇧🇷

Jau, Brazil

Fundacion COIR

🇦🇷

Mendoza, Argentina

University of California

🇺🇸

Los Angeles, California, United States

Yvoir - UNIV UCL de Mont-Godinne

🇧🇪

Yvoir, Belgium

HOP Amiens-Picardie Sud

🇫🇷

Amiens, France

St. Luke's Hospital Association of Duluth, Inc.

🇺🇸

Duluth, Minnesota, United States

HOP Dupuytren 1

🇫🇷

Limoges Cedex 1, France

Univ. Gen. Hosp. of Ioannina

🇬🇷

Ioannina, Greece

HOP Pontchaillou

🇫🇷

Rennes Cedex 9, France

INS Universitaire du Cancer

🇫🇷

Toulouse, France

Hospital Universitario de Salamanca

🇪🇸

Salamanca, Spain

Univ. of Szeged, 2nd Dept. of Internal Med., Haematology

🇭🇺

Szeged, Hungary

University of Fukui Hospital

🇯🇵

Fukui, Yoshida-gun, Japan

Amsterdam UMC Locatie VUMC

🇳🇱

Amsterdam, Netherlands

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Clínic de Barcelona

🇪🇸

Barcelona, Spain

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

City Hospital Torun, Department of Hematology

🇵🇱

Torun, Poland

Hospital La Paz

🇪🇸

Madrid, Spain

Hospital Politècnic La Fe

🇪🇸

Valencia, Spain

St. John Medical College and hospital

🇮🇳

Bangalore, India

Tata Memorial Hospital

🇮🇳

Mumbai, India

LKH-Univ. Hospital Graz

🇦🇹

Graz, Austria

Hospital Hietzing

🇦🇹

Wien, Austria

Sykehuset Østfold Kalnes

🇳🇴

Grålum, Norway

LKH Leoben

🇦🇹

Leoben, Austria

Hospital Universitario Dr Jose Eleuterio Gonzalez

🇲🇽

Monterrey, Mexico

CHULN, EPE - Hospital de Santa Maria

🇵🇹

Lisboa, Portugal

Vancouver General Hospital

🇨🇦

Vancouver, British Columbia, Canada

Meilahden sairaala

🇫🇮

Helsinki, Finland

Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António

🇵🇹

Porto, Portugal

IPO Porto Francisco Gentil, EPE

🇵🇹

Porto, Portugal

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Mackay Memorial Hospital

🇨🇳

Taipei, Taiwan

Haukeland Universitetssykehus

🇳🇴

Bergen, Norway

Chang-Hua Christian Hospital

🇨🇳

ChangHua, Taiwan

Montreal General Hospital - McGill University Health Centre

🇨🇦

Montreal, Quebec, Canada

Klinikum rechts der Isar der Technischen Universität München

🇩🇪

München, Germany

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

🇩🇪

Mainz, Germany

Henry-Joyce Cancer Clinic

🇺🇸

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Hospital Central de Salud Zenón Santillan

🇦🇷

San Miguel de Tucumán, Argentina

AZ Sint-Jan Brugge

🇧🇪

Brugge, Belgium

Jessa Ziekenhuis - Campus Virga Jesse

🇧🇪

Hasselt, Belgium

Brussels - UNIV Saint-Luc

🇧🇪

Bruxelles, Belgium

Roeselare - HOSP AZ Delta

🇧🇪

Roeselare, Belgium

Hospital Mãe de Deus

🇧🇷

Porto Alegre, Brazil

H.C.da Fac. de Medicina de Ribeirao Preto

🇧🇷

Ribeirao Preto, Brazil

University of Alberta Hospital (University of Alberta)

🇨🇦

Edmonton, Alberta, Canada

TYKS, Sisätautien klinikka

🇫🇮

Turku, Finland

Maisonneuve-Rosemont Hospital

🇨🇦

Montreal, Migration Data, Canada

Univ. Hospital Kralovske Vinohrady

🇨🇿

Praha 10, Czechia

Hospital Hradec Kralove

🇨🇿

Hradec Kralove, Czechia

University Hospital Plzen, Plzen-Lochotin

🇨🇿

Plzen - Lochotin, Czechia

HOP Michallon

🇫🇷

La Tronche, France

HOP André Mignot

🇫🇷

Le Chesnay, France

INS Paoli-Calmettes

🇫🇷

Marseille, France

HOP Nantes, Hémato, Nantes

🇫🇷

Nantes, France

HOP Saint-Antoine

🇫🇷

Paris Cedex 12, France

HOP Lyon Sud

🇫🇷

Pierre Bénite, France

Universitätsklinikum Augsburg

🇩🇪

Augsburg, Germany

Med. Klinik m.S. Hämatologie und Onkologie

🇩🇪

Berlin, Germany

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

🇩🇪

Essen, Germany

Städtisches Klinikum Braunschweig gGmbH

🇩🇪

Braunschweig, Germany

Universitätsklinikum Erlangen

🇩🇪

Erlangen, Germany

Universitätsklinikum Frankfurt

🇩🇪

Frankfurt/Main, Germany

Universitätsmedizin Göttingen, Georg-August-Universität

🇩🇪

Göttingen, Germany

Martin-Luther-Universität Halle-Wittenberg

🇩🇪

Halle (Saale), Germany

Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Germany

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

Universitätsklinikum Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel

🇩🇪

Kiel, Germany

Universitätsklinikum Gießen und Marburg GmbH

🇩🇪

Marburg, Germany

General Hospital of Athens "G. Gennimatas"

🇬🇷

Athens, Greece

Schwarzwald-Baar Klinikum

🇩🇪

Villingen-Schwenningen, Germany

Robert-Bosch-Krankenhaus GmbH

🇩🇪

Stuttgart, Germany

Universitätsklinikum Regensburg

🇩🇪

Regensburg, Germany

Universitätsklinikum Ulm

🇩🇪

Ulm, Germany

University of Patras Medical School

🇬🇷

Patras, Greece

General Hospital of Athens "Laiko"

🇬🇷

Athens, Greece

General Hospital of Thessaloniki "G. Papanikolaou"

🇬🇷

Thessaloniki, Greece

Semmelweis University

🇭🇺

Budapest, Hungary

Universitätsklinikum Münster

🇩🇪

Münster, Germany

Petz Aldar Hospital, 2nd Dept. of Internal Med., Haematology

🇭🇺

Gyor, Hungary

A.O. Spedali Civili di Brescia

🇮🇹

Brescia, Italy

ASST Grande Ospedale Metropolitano Niguarda

🇮🇹

Milano, Italy

AO Città della Salute e della

🇮🇹

Torino, Italy

National Hospital Organization Nagoya Medical Center

🇯🇵

Aichi, Nagoya, Japan

Japanese Red Cross Nagoya Daini Hospital

🇯🇵

Aichi, Nagoya, Japan

Akita University Hospital

🇯🇵

Akita, Akita, Japan

Kyushu University Hospital

🇯🇵

Fukuoka, Fukuoka, Japan

Kobe University Hospital

🇯🇵

Hyogo, Kobe, Japan

Osaka City University Hospital

🇯🇵

Osaka, Osaka, Japan

Tokai University Hospital

🇯🇵

Kanagawa, Isehara, Japan

Yokohama City University Medical Center

🇯🇵

Kanagawa, Yokohama, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki, Nagasaki, Japan

Kurashiki Central Hospital

🇯🇵

Okayama, Kurashiki, Japan

Okayama University Hospital

🇯🇵

Okayama, Okayama, Japan

Tohoku University Hospital

🇯🇵

Miyagi, Sendai, Japan

National Cancer Center Hospital

🇯🇵

Tokyo, Chuo-ku, Japan

NTT Medical Center Tokyo

🇯🇵

Tokyo, Sinagawa-ku, Japan

Chonnam National University Hwasun Hospital

🇰🇷

Hwasun, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St.Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Reg. Specialist Hospital of M. Kopernik, Dept. Haematology

🇵🇱

Lodz, Poland

Centro Hospitalar Universitário São João,EPE

🇵🇹

Porto, Portugal

FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF

🇷🇺

Moscow, Russian Federation

Regional Clinical Hospital 'The Badge of Honor Order'

🇷🇺

Irkutsk, Russian Federation

Nizhniy Novgorod Reg. Clinical Hospital, Dept. Haematology

🇷🇺

Nizhniy Novgorod, Russian Federation

Leningrad Reg. Clin. Hosp., Oncohematology Department No. 2

🇷🇺

St. Petersburg, Russian Federation

Hospital Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

Netcare Pretoria East Hospital

🇿🇦

Moreleta Park, Pretoria, South Africa

Hospital Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Germans Trias i Pujol

🇪🇸

Badalona, Spain

UZ Leuven

🇧🇪

Leuven, Belgium

Haine-St-Paul - HOSP Jolimont

🇧🇪

Haine-Saint-Paul, Belgium

Centre Hospitalier Universitaire de Liège

🇧🇪

Liège, Belgium

© Copyright 2025. All Rights Reserved by MedPath